William Armstrong is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2501 Citico Ave
Chattanooga, TN 374041127
Telephone
423-697-2000Provider last certified this registry record 26 May 2020.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Alnylam Pharmaceuticals Inc.Program year20251 payment
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.2%Beta blocker20.8%Carvedilol34%Metoprolol Tartrate31%Metoprolol Succinate28%Propranolol Hcl3%Atenolol2%Bisoprolol Fumarate2%Sotalol1%Part D<11 patientsStatin14.5%Atorvastatin Calcium57%Rosuvastatin Calcium38%Pravastatin Sodium6%Part D≥123 patients+ 17 more classes in this area
Blood & clotting
16.7%Factor Xa inhibitor10.3%Eliquis77%Xarelto23%Part D≥102 patientsP2Y12 inhibitor3.4%Clopidogrel84%Brilinta16%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
3.1%Potassium supplement1.4%Potassium Chloride100%Part D≥29 patientsSGLT2 inhibitor1.2%Jardiance74%Farxiga26%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 1985–2025 per NIH RePORTER. The latest:
- C-type natriuretic peptide in hypertrophic cardiomyopathy
Vanderbilt University Medical Center
FY2025$130,518K99HL171847 - C-type natriuretic peptide in hypertrophic cardiomyopathy
Vanderbilt University Medical Center
FY2024$130,518K99HL171847 - Innovative natriuretic peptide-based therapy for hypertrophic cardiomyopathy
Vanderbilt University Medical Center
FY2023$85,304F32HL165917
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”